Nonstandard and off-label therapies for psoriasis

Clinics in Dermatology

Volumn 26, Issue 5, 2008, Pages 546-553

  Halverstam, Caroline P ^a   Lebwohl, Mark ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COLCHICINE; CYCLOSPORIN; DAPSONE; ERYTHROMYCIN; HYDROXYUREA; ISOTRETINOIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PACLITAXEL; PIMECROLIMUS; PLACEBO; SALAZOSULFAPYRIDINE; TACROLIMUS; TRIPTOLIDE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW TOXICITY; BULLOUS PEMPHIGOID; CLIMATOTHERAPY; CLINICAL TRIAL; DERMATITIS HERPETIFORMIS; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG LABELING; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; GASTROINTESTINAL SYMPTOM; GRENZ RADIATION; HEADACHE; HEARTBURN; HEAT SENSATION; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER TOXICITY; MALAISE; MALE INFERTILITY; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PANCYTOPENIA; PEMPHIGUS VULGARIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUSTULAR PSORIASIS; SIDE EFFECT; SKIN PIGMENTATION; STEATORRHEA; THROMBOCYTOPENIA; VOMITING;

DRUG LABELING; HUMANS; PSORIASIS;

EID: 49849090339     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2007.10.023     Document Type: Article

References (67)

1. Grundmann-Kollmann M., Korting H.C., Behrens S., et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 40 (1999) 957-960
2. Grundmann-Kollmann M., Mooser G., Schraeder P., et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 42 (2000) 835-837
3. Geilen C.C., Arnold M., and Orfanos C.E. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol 144 (2001) 583-586
4. Zhou Y., Rosenthal D., Dutz J., et al. Mycophenolate mofetil (CellCept®) for psoriasis: a two-center, prospective, open-label clinical trial. J Cutan Med Surg (2003) 193-197
5. Ramos-Casals M., and Font J. Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 14 (2005) s64-s72
6. Mathew T.H., and for the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, long-term randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at 3 years. Transplantation 65 (1998) 1450-1454
7. Epinette W.W., Parker C.M., Jones E.L., et al. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy and safety. J Am Acad Dermatol 17 (1987) 962-971
8. Lebwohl M., and Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 45 (2001) 649-661
9. Sherer D., and Lebwohl M. Mycophenolate mofetil for psoriasis. Psoriasis Forum 4 (1998) 6
10. Ortonne J.P., van de Kerkhof P.C.M., Prinz J.C., et al. 0.3% tacrolimus gel and 0.5% tacrolimus cream show efficacy in mild to moderate plaque psoriasis: results of a randomized, open-label, observer-blinded study. Acta Derm Venereol 86 (2005) 29-33
11. Lebwohl M., Freeman A.K., Chapman S., et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 51 (2004) 723-730
12. The European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 132 (1996) 419-423
13. Gribetz C., Ling M., Lebwohl M., et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 51 (2004) 731-738
14. Gottlieb A.B., Griffiths C.E.M., Ho V.C., et al. Oral pimecrolimus in the treatment of moderate to severe chronic plaque psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol 152 (2005) 1219-1227
15. Moy R.L., Kingston T.P., and Lowe N.J. Isotretinoin vs. etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol 121 (1985) 1297-1301
16. Honigsmann H., and Wolff K. Isotretinoin-PUVA for psoriasis. Lancet 1 (1983) 236
17. Sofen H.L., Moy R.L., and Lowe N.J. Treatment of generalized pustular psoriasis with isotretinoin. Lancet 1 (1984) 40
18. Lowe N.J., Lazarus V., and Matt L. Systemic retinoid therapy for psoriasis. J Am Acad Dermatol 19 (1988) 186-191
19. Tan M.H., Solganick J., and Lebwohl M. Adverse effects of systemic psoriasis treatments: retinoids. Psoriasis Forum 3 (1997) 6-7
20. Wahba A., and Cohen H. Therapeutic trials with oral colchicine in psoriasis. Acta Derm Venereol 60 (1980) 515-520
21. McKendry R.J., Kraag G., Seigel S., et al. Therapeutic value of colchicine in the treatment of patients with psoriatic arthritis. Ann Rheum Dis 52 (1993) 826-828
22. Zachariae H., Kragballe K., and Herlin T. Colchicine in generalized pustular psoriasis: clinical response and antibody-dependent cytotoxicity by monocytes and neutrophils. Arch Dermatol Res 274 (1982) 327-333
23. Wong S.S., Tan K.C., and Goh C.L. Long-term colchicine for recalcitrant palmoplantar pustulosis: treatment outcome in 3 patients. Cutis 68 (2001) 216-218
24. Takigawa M., Miyachi Y., Uehara M., et al. Treatment of pustulosis palmaris et plantaris with oral doses of colchicine. Arch Dermatol 118 (1982) 458-460
25. Thestrup-Pedersen K., and Reymann F. Treatment of pustulosis palmaris et plantaris with colchicine. A double-blind cross-over trial. Acta Derm Venereol 64 (1984) 76-78
26. Sullivan T.P., King Jr. L.E., and Boyd A.S. Colchicine in dermatology. J Am Acad Dermatol 39 (1998) 993-999
27. UpToDate. Colchicine: drug information. Available at:. http://uptodate.com [Accessed August 12, 2006]
28. Halasz C.L.G. Sulfasalazine as folic acid inhibitor in psoriasis. Arch Dermatol 126 (1990) 1516
29. Gupta A.K., Ellis C.N., Siegel M.T., et al. Sulfasalazine improves psoriasis. A double-blind analysis. Arch Dermatol 126 (1990) 487-493
30. Gupta A.K., Grober J.S., Hamilton T.A., et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 22 (1995) 894-898
31. Clegg D.O., Reda D.J., Mejias E., et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39 (1996) 2013-2020
32. Rahman P., Gladman D.D., Cook R.J., et al. The use of sulfasalazine in psoriatic arthritis: a clinical experience. J Rheumatol 25 (1998) 1957-1961
33. Watkinson G. Sulphasalazine: a review of 40 years' experience. Drugs 32 suppl 1 (1986) 1-11
34. Cohen A.D., Van-Dijk D., Naggan L., et al. Effectiveness of climatotherapy at the Dead Sea for psoriasis vulgaris: a community-oriented study introducing the 'Beer Sheva Psoriasis Severity Score'. J Derm Treat 16 (2005) 308-313
35. Hodak E., Gottlieb A.B., Segal T., et al. Climatotherapy at the Dead Sea is a remittive therapy for psoriasis: combined effects on epidermal and immunologic activation. J Am Acad Dermatol 49 (2003) 451-457
36. Shani J., Harari M., Hristakieva E., et al. Dead-Sea climatotherapy versus other modalities of treatment for psoriasis: comparative cost-effectiveness. Int J Dermatol 38 (1999) 252-262
37. David M., Tsukrov B., Adler B., et al. Actinic damage among patients with psoriasis treated by climatotherapy at the Dead Sea. J Am Acad Dermatol 52 (2005) 445-450
38. Gambichler T., Altmeyer P., and Hoffmann K. Cost-effectiveness of Dead-Sea climatotherapy and balneophototherapy of psoriasis. Int J Dermatol 40 (2001) 158-160
39. Gambichler T., Kuster W., Kreuter A., et al. Balneophototherapy-combined treatment of psoriasis vulgaris and atopic dermatitis with salt water baths and artificial ultraviolet radiation. J Eur Acad Dermatol Venereol 14 (2000) 425-428
40. Ehrlich A., Booher S., Becerra Y., et al. Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J Am Acad Dermatol 50 (2004) 533-540
41. Taxol. Physicians' desk reference. 56th ed. (2002), Medical Economics Company, Inc, Montvale (NJ) 1129-1138
42. MacMillan A.L., and Champion R.H. Generalized pustular psoriasis treated with dapsone. Br J Dermatol 88 (1973) 183-185
43. Peachey R.D.G. Atypical pustular psoriasis treated with dapsone. Br J Dermatol 97 suppl 15 (1977) 64-66
44. Juanqin G., Zhiqiang C., and Zijia H. Evaluation of the effectiveness of childhood generalized pustular psoriasis treatment in 30 cases. Pediatr Dermatol 15 (1998) 144-146
45. Mazzatenta C., Martini P., Luti L., et al. Diffuse sterile pustular eruption with changing clinical features in a 2-year-old. Pediatr Dermatol 22 (2005) 250-253
46. Zhu Y.I., and Stiller M.J. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 45 (2001) 420-434
47. UpToDate. Dapsone: drug information. Available at:. http://uptodate.com [Accessed August 12, 2006]
48. Dapsone tablets USP. Physicians' desk reference. 60th ed. (2006), Thomas PDR, Montvale (NJ) 1656-1657
49. Du A., and Vivier D.D. Verbov: treatment of psoriasis with azathioprine. BMJ 1 (1974) 49-51
50. Greaves M.W., and Dawber R. Azathioprine in psoriasis. BMJ 2 (1970) 237-238
51. Roeder C., and von den Driesch P. Psoriatic erythroderma and bullous pemphigoid treated successfully with acitretin and azathioprine. Eur J Dermatol 9 (1999) 537-539
52. Primka E.J., and Camisa C. Psoriasis and bullous pemphigoid treated with azathioprine. J Am Acad Dermatol 39 (1998) 121-123
53. Gendler E. Azathioprine for use in dermatology. J Dermatol Surg Oncol 10 (1984) 462-464
54. UpToDate. Azathioprine: drug information. Available at:. http://uptodate.com [Accessed August 12, 2006]
55. Azasan. Physicians' desk reference. 60th ed. (2006), Thomas PDR, Montvale (NJ) 2844-2845
56. Kumar B., Saraswat A., and Kaur I. Rediscovering hydroxyurea: its role in recalcitrant psoriasis. Int J Dermatol 40 (2001) 530-534
57. Smith C.H. Use of hydroxyurea in psoriasis. Clin Exp Dermatol 24 (1999) 2-6
58. Hattel T., and Sondergaard J. Pustulosis palmaris et plantaris treated with hydroxyurea. Acta Derm Venereol 54 (1974) 152-154
59. Lori F., and Lisziewicz J. Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects. Antivir Ther 4 suppl 3 (1999) 101-108
60. Lafeuillade A., Hittinger G., Chadapaud S., et al. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations. HIV Clin Trials 3 (2002) 263-271
61. Johannesson A., and Lindelof B. The effect of grenz rays on psoriasis lesions of the scalp: a double-blind bilateral trial. Photodermatology 2 (1985) 388-391
62. Johannesson A., and Lindelof B. Additional effect of grenz rays on psoriasis lesions of the scalp treated with topical corticosteroids. Dermatologica 175 (1987) 290-292
63. Lindelof B., and Johannesson A. Psoriasis of the scalp treated with grenz rays or topical corticosteroid combined with grenz rays. A comparative randomized trial. Br J Dermatol 119 (1988) 241-244
64. Lindelof B. Psoriasis of the nails treated with grenz rays: a double-blind bilateral trial. Acta Derm Venereol 69 (1989) 80-82
65. Lindelof B., and Beitner H. The effect of grenz ray therapy on pustulosis palmoplantaris. A double blind bilateral trial. Acta Derm Venereol 70 (1990) 529-531
66. Lindelof B. Grenz ray therapy in dermatology. An experimental, clinical and epidemiological study. Acta Derm Venereol 132 suppl (1987) 1-67
67. Lindelof B., and Eklund G. Incidence of malignant skin tumors in 14,140 patients after grenz-ray treatment for benign skin disorders. Arch Dermatol 122 (1986) 1391-1395